166 related articles for article (PubMed ID: 35121033)
21. Mutational Status and Clinical Outcomes Following Systemic Therapy with or without Focal Radiation for Resected Melanoma Brain Metastases.
Vasudevan HN; Susko MS; Ma L; Nakamura JL; Raleigh DR; Boreta L; Fogh S; Theodosopoulos PV; McDermott MW; Tsai KK; Sneed PK; Braunstein SE
World Neurosurg; 2023 Feb; 170():e514-e519. PubMed ID: 36400359
[TBL] [Abstract][Full Text] [Related]
22. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF
van Breeschoten J; Wouters MWJM; Hilarius DL; Haanen JB; Blank CU; Aarts MJB; van den Berkmortel FWPJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Blokx WAM; Tije BJT; Veldt AAMV; Vreugdenhil A; Boers-Sonderen MJ; van den Eertwegh AJM
Br J Cancer; 2021 Mar; 124(7):1222-1230. PubMed ID: 33495600
[TBL] [Abstract][Full Text] [Related]
23. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China.
Wang Y; Lian B; Si L; Chi Z; Sheng X; Wang X; Mao L; Tang B; Li S; Yan X; Bai X; Zhou L; Cui C; Guo J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2731-2740. PubMed ID: 33611636
[TBL] [Abstract][Full Text] [Related]
24. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.
Ly D; Bagshaw HP; Anker CJ; Tward JD; Grossmann KF; Jensen RL; Shrieve DC
J Neurosurg; 2015 Aug; 123(2):395-401. PubMed ID: 25768829
[TBL] [Abstract][Full Text] [Related]
25. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.
Czarnecka AM; Teterycz P; Mariuk-Jarema A; Lugowska I; Rogala P; Dudzisz-Sledz M; Switaj T; Rutkowski P
Target Oncol; 2019 Dec; 14(6):729-742. PubMed ID: 31754963
[TBL] [Abstract][Full Text] [Related]
26. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
27. Advances in the systemic treatment of melanoma brain metastases.
Glitza Oliva IC; Schvartsman G; Tawbi H
Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
[TBL] [Abstract][Full Text] [Related]
28. Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
Patel BG; Ahmed KA; Johnstone PA; Yu HH; Etame AB
Melanoma Res; 2016 Aug; 26(4):382-6. PubMed ID: 26926151
[TBL] [Abstract][Full Text] [Related]
29. Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice.
Fong CH; Meti N; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; de Moraes FY; Dasgupta A; Ong CK; Yang JCH; Lee JH; Kosyak N; Pavlakis N; Kongkham P; Doherty M; Leighl NB; Shultz DB
J Thorac Dis; 2023 Aug; 15(8):4367-4378. PubMed ID: 37691657
[TBL] [Abstract][Full Text] [Related]
30. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
31. Commentary: BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction with Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.
Lukas RV
Neurosurgery; 2019 Apr; 84(4):881-882. PubMed ID: 29846721
[No Abstract] [Full Text] [Related]
32. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
[TBL] [Abstract][Full Text] [Related]
33. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
34. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
35. Melanoma brain metastases: Biological basis and novel therapeutic strategies.
Phadke M; Ozgun A; Eroglu Z; Smalley KSM
Exp Dermatol; 2022 Jan; 31(1):31-42. PubMed ID: 33455008
[TBL] [Abstract][Full Text] [Related]
36. Frequent brain metastases during treatment with BRAF/MEK inhibitors: A retrospective single institutional study.
Nakamura Y; Ishitsuka Y; Tanaka R; Okiyama N; Watanabe R; Saito A; Furuta J; Fujisawa Y
J Dermatol; 2020 Oct; 47(10):1191-1194. PubMed ID: 32602174
[TBL] [Abstract][Full Text] [Related]
37. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
38. BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis.
Patel KR; Chowdhary M; Switchenko JM; Kudchadkar R; Lawson DH; Cassidy RJ; Prabhu RS; Khan MK
Melanoma Res; 2016 Aug; 26(4):387-94. PubMed ID: 27223498
[TBL] [Abstract][Full Text] [Related]
39. Real-world data on melanoma brain metastases and survival outcome.
Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E
Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571
[TBL] [Abstract][Full Text] [Related]
40. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
